Business

MOBILion Systems is the latest medtech company to receive venture capital funding, raising $35 million in a series B round.

During a May earnings call, Medtronic executives expressed an appetite for M&A and pointed out it is a good time for deals.

Qiagen is now expected to pay Thermo Fisher Scientific an expense reimbursement payment of $95 million in accordance with the acquisition agreement.

The transaction is valued at $18.5 billion and it is one of the largest medtech deals this year.

The Seattle, WA-based company will gain access to Dana’s AI/ML-based platforms and PhenoTox, a deep learning platform for predictive safety pharmacology.

The San Diego, CA-based company was able to attract investors because it had already made significant progress in the development of its gastrointestinal tests.

The New Brunswick, NJ-based company won’t pursue a 510(k) pathway for the platform and will have first-in-human studies in the late half of 2022.